Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
17.63
+0.35 (2.03%)
Jul 2, 2026, 4:00 PM EDT - Market closed
Cullinan Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
109
Market Cap
1.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 18.94M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 369.49M |
| Xencor | 97.36M |
| Kura Oncology | 71.64M |
| Lexicon Pharmaceuticals | 69.64M |
| EyePoint | 7.61M |
| Avalo Therapeutics | 59.00K |
CGEM News
- 24 days ago - Cullinan Therapeutics price target raised to $46 from $33 at Clear Street - TheFly
- 24 days ago - Cullinan Therapeutics Transcript: Immunology Day 2026 - Transcripts
- 24 days ago - Cullinan Therapeutics Slides: FY 2026 - Filings
- 24 days ago - Cullinan Therapeutics Press release: FY 2026 - Filings
- 25 days ago - Cullinan Therapeutics reports CLN-978, velinotamig data - TheFly
- 25 days ago - Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases - GlobeNewsWire
- 27 days ago - Cullinan Therapeutics presents clinical data for CLN-978 - TheFly
- 5 weeks ago - Cullinan to host Immunology Day event, announce data for CLN-978, Velinotamig - TheFly